UNITED THERAPEUTICS $UTHR Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $832.5M (Est. $781M) 🟢; +4% YoY 🔹 EPS: $5.71 (Est. $6.42) 🔴; -20% YoY 🔹 Operating Income: $307.8M (Est. $347M) 🔴 Revenue Breakdown: 🔹 Tyvaso DPI: $378.5M; +13% YoY 🔹 Nebulized Tyvaso: $125.3M; -12% YoY 🔹 Orenitram: $145.0M; +11% YoY 🔹 Remodulin: $122.0M; -3% YoY 🔹 Adcirca: $4.5M; -54% YoY Announcements: 🔹 Share Repurchase: Up to $2.0B authorized through October 21, 2027 Key Updates: 🔹 Other R&D: $130.0M, primarily tied to Thymmune acquisition IPR&D Comments: 🔸 “United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve.” 🔸 “Our strategies are delivering, securing an increasingly strong position to leverage our commercial operations. With a durable and robust foundation combined with significant new opportunities across cardiopulmonary and respiratory medicine rapidly approaching, we believe we have the strongest growth outlook in our history.”